Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Longrée

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Revue Medicale De Liege|May 1, 1993
[Continuous administration of anti-cancer chemotherapy. Theoretical basis and literature review]L Longrée, C Focan
Revue Medicale De Liege|October 1, 1988
[Alteration in general status and polyadenopathies in a 66-year-old man]L Longrée, P Michel, J Boniver, et al.
Revue Medicale De Liege|August 12, 2020
[Schnitzler syndrome]C Ilbert, M Sabatiello, W Kurth, et al.
Revue Medicale De Liege|December 19, 1998
[Clinical case of the month. Metastatic endocarditis: clinical observation and review of the literature]M P Graas, P Evrard, E Creemers, et al.
Pathologie-Biologie|June 9, 2005
[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer]C Focan, F Kreutz, M P Graas, et al.
Pathologie-Biologie|April 10, 2007
[Interest of chronotherapy in multidisciplinary management of oesophageal and gastric cancers]C Focan, F Kreutz, L Longrée, et al.
Pathologie-Biologie|October 30, 2012
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 studyC Focan, F Kreutz, M-P Graas, et al.
Pathologie-Biologie|October 24, 2012
[Chronotherapy with 5-fluorouracil folinic acid and oxaliplatin delivered over 48 hours every second week in colorectal cancer. The CHC-Liège experience (Belgium)]C Focan, G Demolin, F Kreutz, et al.
Revue Medicale De Liege|April 1, 1989
[Parathyroid carcinoma]L Longrée, B Massart, E Firre, et al.
Anticancer Research|July 1, 1995
Levamisole adds granulocyte toxicity to 5FU-based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary reportL Longrée, C Focan, J Bury, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Revue Medicale De Liege|May 1, 1993
[Continuous administration of anti-cancer chemotherapy. Theoretical basis and literature review]L Longrée, C Focan
Revue Medicale De Liege|October 1, 1988
[Alteration in general status and polyadenopathies in a 66-year-old man]L Longrée, P Michel, J Boniver, et al.
Revue Medicale De Liege|August 12, 2020
[Schnitzler syndrome]C Ilbert, M Sabatiello, W Kurth, et al.
Revue Medicale De Liege|December 19, 1998
[Clinical case of the month. Metastatic endocarditis: clinical observation and review of the literature]M P Graas, P Evrard, E Creemers, et al.
Pathologie-Biologie|June 9, 2005
[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer]C Focan, F Kreutz, M P Graas, et al.
Pathologie-Biologie|April 10, 2007
[Interest of chronotherapy in multidisciplinary management of oesophageal and gastric cancers]C Focan, F Kreutz, L Longrée, et al.
Pathologie-Biologie|October 30, 2012
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 studyC Focan, F Kreutz, M-P Graas, et al.
Pathologie-Biologie|October 24, 2012
[Chronotherapy with 5-fluorouracil folinic acid and oxaliplatin delivered over 48 hours every second week in colorectal cancer. The CHC-Liège experience (Belgium)]C Focan, G Demolin, F Kreutz, et al.
Revue Medicale De Liege|April 1, 1989
[Parathyroid carcinoma]L Longrée, B Massart, E Firre, et al.
Anticancer Research|July 1, 1995
Levamisole adds granulocyte toxicity to 5FU-based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary reportL Longrée, C Focan, J Bury, et al.
Pageof 2